Panel discussion on “Key to Clinical Success in Cell and Gene Therapy: from Bench to Bedside”

Dr. Ivan Horak, CEO and Founder of Tikva Allocell, shared his insights as panelist at the event, “Key to Clinical Success in Cell and Gene Therapy: from Bench to Bedside”

SINGAPORE – 26 Apr 2024 – In a networking event held on 28 March 2024, “Key to Clinical Success in Cell and Gene Therapy: from Bench to Bedside”, Dr. Ivan Horak, Founder and CEO of Tikva Allocell shared his experience and insights on the opportunities and challenges facing the cell and gene therapy (CGT) industry.

The event, co-organized by Biotech Connection Singapore and Labcorp, saw an enthusiastic turnout of scientists and clinicians, academic researchers and industry leaders. The panel was expertly moderated by A/Prof Danny Soon, CEO of CRIS and Interim Executive Director of Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), and the other distinguished panelists were Dr. Maryland Rosenfeld Franklin, VP and Enterprise Head of Cell & Gene Therapy, Labcorp, and Dr. Qi-Jing Li, Chief Innovation Officer, Institute of Molecular and Cell Biology (IMCB), Research Director of IMCB & SIgN, Co-Founder of HRain Biotech, TCRCure Biopharma Corp. and Hervor Therapeutics.

The enriching discussion ranged from optimizing biomanufacturing processes, conducting clinical trials, and the role of biomarkers in the development of cell and gene therapy. The panelists also had engaging exchanges with the audience, providing valuable insights on the importance of preclinical studies, the current regulatory requirements, and the most recent technological advances in the CGT space. There is palpable excitement among the attendees of the event as the innovation of cell and gene therapy continues to progress to improve clinical outcomes for patients.

Tong Cheuk Ka, PhD

Director, Strategy and External Collaborations

Cheuk Ka has program management and translational research experience in biotech companies and academic institutes. She has led cross-functional teams to achieve IND filing with FDA, and progress of pipeline products from preclinical to clinical studies. At Tikva Allocell, she establishes strategic partnerships to advance the development of cell therapies for the treatment of cancers.

Share the Post:

Related Posts